Ivabradine (Procoralan) for the indication chronic heart failure
Ivabradine has an added therapeutic value in comparison with placebo in patients with chronic heart failure HYHA class II-IV in sinus rhythm with systolic dysfunction with a resting heart rate of ≥75 bpm if it is added to an individually determined and optimally dosed medicinal treatment drawn up in accordance with guidelines, and including, in principle, an ACE inhibitor, a diuretic, a beta-blocker and an anti-aldosterone agent, unless this is contraindicated or not tolerated by the patient.